More intelligent intervention through more strategic use of CV biomarkers - PACE-CME

More intelligent intervention through more strategic use of CV biomarkers

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Moving from ignorance on the complexity of HDL to novel therapeutic opportunities
Moving from ignorance on the complexity of HDL to novel therapeutic opportunities
EAS 2019
Moving from ignorance on the complexity of HDL to novel therapeutic opportunities
Reduced Lp(a) with PCSK9 inhibitors in individuals with high Lp(a) at baseline contributes to CV risk reduction
Reduced Lp(a) with PCSK9 inhibitors in individuals with high Lp(a) at baseline contributes to CV risk reduction
EAS 2019
Reduced Lp(a) with PCSK9 inhibitors in individuals with high Lp(a) at baseline contributes to CV risk reduction
- Prof. Chapman
Positive phase II trial data with novel anti-PCSK9 agent
Positive phase II trial data with novel anti-PCSK9 agent
EAS 2019
Positive phase II trial data with novel anti-PCSK9 agent
- Evan Stein, MD, PhD
Efforts to move universal cholesterol screening before the age of 20 forward
Efforts to move universal cholesterol screening before the age of 20 forward
EAS 2019
Efforts to move universal cholesterol screening before the age of 20 forward
- Professor Kausik Ray, MD